Sarepta Therapeutics, Inc. (SRPT)

$137.94

+7.44

(+5.7%)▲

Market is closed - opens 8 PM, 29 Nov 2024

Performance

  • $130.00
    $138.01
    $137.94
    downward going graph

    5.76%

    Downside

    Day's Volatility :5.8%

    Upside

    0.05%

    downward going graph
  • $78.67
    $173.25
    $137.94
    downward going graph

    42.97%

    Downside

    52 Weeks Volatility :54.59%

    Upside

    20.38%

    downward going graph

Returns

PeriodSarepta Therapeutics, Inc.Sector (Health Care)Index (Russel 2000)
3 Months
-7.22%
-6.1%
0.0%
6 Months
15.15%
1.2%
0.0%
1 Year
58.03%
12.2%
0.0%
3 Years
63.41%
10.8%
-21.2%

Highlights

Market Capitalization
10.9B
Book Value
$12.79
Earnings Per Share (EPS)
1.54
PE Ratio
74.18
PEG Ratio
159.25
Wall Street Target Price
189.625
Profit Margin
7.43%
Operating Margin TTM
4.75%
Return On Assets TTM
1.51%
Return On Equity TTM
12.27%
Revenue TTM
1.6B
Revenue Per Share TTM
16.92
Quarterly Revenue Growth YOY
40.8%
Gross Profit TTM
-78.1M
EBITDA
119.7M
Diluted Eps TTM
1.54
Quarterly Earnings Growth YOY
0.0
EPS Estimate Current Year
3.83
EPS Estimate Next Year
12.55
EPS Estimate Current Quarter
-0.13
EPS Estimate Next Quarter
1.37

Analyst Recommendation

Buy
    82%Buy
    17%Hold
    0
    0%Sell
Based on 29 Wall street analysts offering stock ratings for Sarepta Therapeutics, Inc.(by analysts ranked 0 to 5 stars)
Based on 29 analyst
  • Current
  • 1M Ago
  • 3M Ago
Buy
24
25
25
Hold
5
5
5
Sell
00
00
00

Analyst Forecast

What analysts predicted

Upside of 37.47%

Current $137.94
Target $189.62

Technicals Summary

Sell

Neutral

Buy

Sarepta Therapeutics, Inc. is currently in a neutral trading position according to technical analysis indicators.

More on Technical Analysis

Peers

Company Name1 Month6 Month1 Year3 Years5 Years
Sarepta Therapeutics, Inc.
Sarepta Therapeutics, Inc.
0.18%
15.15%
58.03%
63.41%
17.65%
Regeneron Pharmaceuticals, Inc.
Regeneron Pharmaceuticals, Inc.
-18.91%
-22.62%
-5.64%
15.07%
102.66%
Biontech Se
Biontech Se
4.66%
25.97%
22.38%
-67.3%
441.77%
Alnylam Pharmaceuticals, Inc.
Alnylam Pharmaceuticals, Inc.
-11.7%
68.83%
59.14%
40.17%
115.51%
Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals Incorporated
-1.95%
4.52%
33.38%
145.68%
112.25%
Company NameP/E RatioP/B RatioPEG RatioEPSROEROADiv YieldBVPS
Sarepta Therapeutics, Inc.
Sarepta Therapeutics, Inc.
74.18
74.18
159.25
3.83
0.12
0.02
NA
12.79
Regeneron Pharmaceuticals, Inc.
Regeneron Pharmaceuticals, Inc.
18.25
18.25
1.1
44.91
0.17
0.07
NA
272.04
Biontech Se
Biontech Se
160.8
NA
0.04
-3.04
-0.02
-0.01
NA
79.73
Alnylam Pharmaceuticals, Inc.
Alnylam Pharmaceuticals, Inc.
NA
NA
-0.49
-0.17
-15.01
-0.03
NA
0.25
Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals Incorporated
32.84
NA
1.21
0.54
-0.03
0.12
NA
60.65
Company NameAnalyst ViewMarket Cap5 Years Return %PE RatioProfit Margin
Sarepta Therapeutics, Inc.
Sarepta Therapeutics, Inc.
Buy
$10.9B
17.65%
74.18
7.43%
Regeneron Pharmaceuticals, Inc.
Regeneron Pharmaceuticals, Inc.
Buy
$81.1B
102.66%
18.25
33.61%
Biontech Se
Biontech Se
Buy
$27.1B
441.77%
160.8
-15.36%
Alnylam Pharmaceuticals, Inc.
Alnylam Pharmaceuticals, Inc.
Buy
$31.6B
115.51%
NA
-15.86%
Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals Incorporated
Buy
$118.9B
112.25%
32.84
-4.51%

Insights on Sarepta Therapeutics, Inc.

  • Increasing Revenue

    Revenue is up for the last 2 quarters, 362.93M → 467.17M (in $), with an average increase of 22.3% per quarter

  • Increasing Net Profit

    Netprofit is up for the last 2 quarters, 6.46M → 33.61M (in $), with an average increase of 80.8% per quarter

  • Vs ALNY

    In the last 1 year, Alnylam Pharmaceuticals, Inc. has given 59.1% return, outperforming this stock by 1.1%

Institutional Holdings

  • BlackRock Inc

    10.81%

  • Vanguard Group Inc

    9.39%

  • Capital Research & Mgmt Co - Division 3

    6.55%

  • Morgan Stanley - Brokerage Accounts

    5.49%

  • State Street Corp

    4.34%

  • HHG PLC

    4.00%

Company Information

sarepta therapeutics is a biopharmaceutical company focused on the discovery and development of unique rna-targeted therapeutics for the treatment of rare, infectious and other diseases. the company is primarily focused on rapidly advancing the development of its potentially disease-modifying dmd drug candidates, including its lead dmd product candidate, eteplirsen, designed to skip exon 51. sarepta is also developing therapeutics for the treatment of infectious diseases, such as drug-resistant bacteria and other rare human diseases. for more information, please visit us at www.sarepta.com.

Organization
Sarepta Therapeutics, Inc.
Employees
1314
CEO
Mr. Douglas S. Ingram Esq.
Industry
Health Technology

FAQs